Navigation Links
Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
Date:9/6/2011

MALVERN, Pa., Sept. 6, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced a safety update following 17 months of post-approval use in the U.S. of XIAFLEX® for the treatment of adult Dupuytren's contracture patients with a palpable cord.  After approximately 11,000 injections administered to approximately 10,000 patients in the U.S., there was no clinically meaningful change in the nature of events expected relative to the clinical trial safety profile.  

From February 2, 2010 through June 30, 2011, approximately 560 adverse events have been reported to the Company. Of those events, local events such as skin laceration, swelling and bruising at the site of injection were the most commonly reported events representing 15%, 11.8% and 10.9% of the event reports, respectively.  Less commonly reported events included injection site hematoma and pain. Adverse event reporting requirements post-approval are different from requirements for reporting such events during a clinical trial.  See "About Voluntary Safety Reporting" below.

In the clinical trials, three (0.3%) subjects experienced a tendon rupture and one (0.1%) subject experienced ligament damage (pulley rupture) following XIAFLEX treatment of 1,082 subjects in the safety database.    Approximately 60 clinical investigators injected XIAFLEX during the clinical trials.  In the post-approval period, five tendon ruptures (0.05%) and two ligament injuries (0.02%) were reported.  There have been no reports of complex regional pain syndrome or nerve injury to date.  Since launch, approximately 1,230 U.S. physicians have injected Dupuytren's contracture patients with XIAFLEX.

"Based on reported events, we believe that XIAFLEX has demonstrated a safety profile in post-approval use that is consistent w
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
4. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
5. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
7. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
10. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
11. ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... India Solid Waste Management Vehicles Market Forecast ... In India ... responsible for complete handling and regulation of solid ... 135,000 MT solid waste is generated daily in ...
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... Innovation, Inc. (BHI), a regional private-public partnership focusing ... early-stage funding in Central Maryland, announced today the appointment ... at Qiagen , to its Board of ... to our board," said Scott Carmer, BioHealth Innovation, Inc. ...
... by Kathleen Eggleson, a research scientist in the Center ... of Notre Dame, provides an example of a nanotechnology-related ... The world of nanotechnology, which involves science and ... But like most new advances, the application of that ...
... On April 19, 2012, GeneLink,s common stock began trading ... this will be temporary as it is due to the ... for the period ended December 31, 2011.  The Company anticipates ... on Form 10K for the period ended December 31, 2011 ...
Cached Biology Technology:BioHealth Innovation, Inc. Appoints Qiagen's Douglas Liu to Board of Directors 2Notre Dame paper examines nanotechnology-related safety and ethics problem 2Notre Dame paper examines nanotechnology-related safety and ethics problem 3GeneLink Anticipates Completion of Audit 2
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... the same DNA sequence their genetic information. How ... in the different parts of the body are so ... master plan, an additional regulatory layer exists that determines ... This mechanism involves modifications of genome-bound histone proteins or ... It acts on top of the genetic information and ...
(Date:9/2/2014)... the September issue of The FASEB Journal ... to diagnose the leading cause of blindness in ... occurred. This advance involves quantifying the early molecular ... retinal vessels. Using new probes developed by scientists, ... development of diabetic retinopathy. , "My goal is ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... Scientists have discovered that a stem cell factor overexpressed ... brain injury promotes tumor survival by inducing angiogenesis. The ... Cell, examines the interaction between tumor cells and surrounding ... more effective therapeutics for one of the most lethal ...
... In an unexpected discovery, scientists at Jefferson Medical College ... virus protein can turn a "safe" virus extremely deadly. ... vaccine they previously created against rabies in wildlife, making ... a molecular mechanism involved in making the rabies virus ...
... disease in the brain of the fruit fly, researchers ... proteins previously associated with cancer. , The findings are ... Brigham and Women's Hospital, Harvard Medical School, and the ... not divide. It is therefore perplexing that in Alzheimer's ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Jefferson researchers building a better rabies vaccine 2
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: